Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.

Sleijfer S, Rizzo E, Litière S, Mathijssen RHJ, Judson IR, Gelderblom H, Van Der Graaf WTA, Gronchi A.

Acta Oncol. 2018 Aug;57(8):1117-1126. doi: 10.1080/0284186X.2018.1449248. Epub 2018 Mar 9.

PMID:
29521151
2.

Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study.

Gelderblom H, Judson IR, Benson C, Merimsky O, Grignani G, Katz D, Freivogel KW, Stein D, Jobanputra M, Mungul A, Manson SC, Sanfilippo R.

Acta Oncol. 2017 Dec;56(12):1769-1775. doi: 10.1080/0284186X.2017.1332779. Epub 2017 Jul 19.

PMID:
28723233
3.

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.

Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schöffski P, Leyvraz S, Italiano A, Grünwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litière S, Marreaud S, van der Graaf W, Gronchi A, Verweij J; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group.

J Clin Oncol. 2017 May 20;35(15):1713-1720. doi: 10.1200/JCO.2016.71.0228. Epub 2017 Mar 31.

PMID:
28362562
4.

Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts.

van der Graaf WT, Orbach D, Judson IR, Ferrari A.

Lancet Oncol. 2017 Mar;18(3):e166-e175. doi: 10.1016/S1470-2045(17)30099-2. Epub 2017 Mar 2. Review.

PMID:
28271871
5.

PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P.

J Clin Oncol. 2016 Nov 10;34(32):3898-3905. doi: 10.1200/JCO.2016.67.6684. Epub 2016 Sep 30.

PMID:
27621408
6.

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.

Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcberg JR, Litière S, Blay JY.

J Clin Oncol. 2015 Dec 20;33(36):4276-83. doi: 10.1200/JCO.2015.62.4304. Epub 2015 Nov 16.

PMID:
26573069
7.

Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.

Lee CP, Taylor NJ, Attard G, Pacey S, Nathan PD, de Bono JS, Temple G, Bell S, Stefanic M, Stopfer P, Tang A, Koh DM, Collins DJ, d'Arcy J, Padhani AR, Leach MO, Judson IR, Rustin GJ.

Oncologist. 2015 Apr;20(4):368-9. doi: 10.1634/theoncologist.2014-0250. Epub 2015 Mar 20.

8.

Targeting protein kinase C in sarcoma.

Martin-Liberal J, Cameron AJ, Claus J, Judson IR, Parker PJ, Linch M.

Biochim Biophys Acta. 2014 Dec;1846(2):547-59. doi: 10.1016/j.bbcan.2014.10.002. Epub 2014 Oct 16. Review.

PMID:
25453364
9.

Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience.

Frezza AM, Benson C, Judson IR, Litiere S, Marreaud S, Sleijfer S, Blay JY, Dewji R, Fisher C, van der Graaf W, Hayward L.

Clin Sarcoma Res. 2014 Jul 29;4:7. doi: 10.1186/2045-3329-4-7. eCollection 2014.

10.

Uterine sarcoma dissemination during myomectomy: if not "acceptable collateral damage," is it possible to mitigate the risk?

Judson IR, Miah AB.

Cancer. 2014 Oct 15;120(20):3100-2. doi: 10.1002/cncr.28841. Epub 2014 Jun 12. No abstract available.

11.

Dichloroacetate induces autophagy in colorectal cancer cells and tumours.

Lin G, Hill DK, Andrejeva G, Boult JK, Troy H, Fong AC, Orton MR, Panek R, Parkes HG, Jafar M, Koh DM, Robinson SP, Judson IR, Griffiths JR, Leach MO, Eykyn TR, Chung YL.

Br J Cancer. 2014 Jul 15;111(2):375-85. doi: 10.1038/bjc.2014.281. Epub 2014 Jun 3.

12.

Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.

Linch M, Miah AB, Thway K, Judson IR, Benson C.

Nat Rev Clin Oncol. 2014 Apr;11(4):187-202. doi: 10.1038/nrclinonc.2014.26. Epub 2014 Mar 18. Review.

PMID:
24642677
13.

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group.

Lancet. 2012 May 19;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5. Epub 2012 May 16.

14.

Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers.

Beloueche-Babari M, Arunan V, Troy H, te Poele RH, te Fong AC, Jackson LE, Payne GS, Griffiths JR, Judson IR, Workman P, Leach MO, Chung YL.

Cancer Res. 2012 Feb 15;72(4):990-1000. doi: 10.1158/0008-5472.CAN-11-2688. Epub 2011 Dec 22.

15.

Potential role of phytoestrogens in the pathophysiology of fibromatosis.

Thanopoulou E, Trehan P, Judson IR.

Ann Oncol. 2011 Dec;22(12):2697-8. doi: 10.1093/annonc/mdr462. Epub 2011 Oct 4. No abstract available.

PMID:
21976388
16.

Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations.

Olmos D, Martins AS, Jones RL, Alam S, Scurr M, Judson IR.

Sarcoma. 2011;2011:402508. doi: 10.1155/2011/402508. Epub 2011 May 3.

17.

Role of palliative chemotherapy in advanced epithelioid sarcoma.

Jones RL, Constantinidou A, Olmos D, Thway K, Fisher C, Al-Muderis O, Scurr M, Judson IR.

Am J Clin Oncol. 2012 Aug;35(4):351-7. doi: 10.1097/COC.0b013e3182118cf7.

PMID:
21422990
18.

Clinical benefit of early phase clinical trial participation for advanced sarcoma patients.

Jones RL, Olmos D, Thway K, Fisher C, Tunariu N, Postel-Vinay S, Scurr M, de Bono J, Kaye SB, Judson IR.

Cancer Chemother Pharmacol. 2011 Aug;68(2):423-9. doi: 10.1007/s00280-010-1484-9. Epub 2010 Nov 11.

PMID:
21069341
19.

Fungal spinal cord compression in metastatic synovial sarcoma.

Ratnayake G, Judson IR, Scurr M, Thway K, Fisher C, Jones RL.

Acta Oncol. 2011 Jan;50(1):158-9. doi: 10.3109/0284186X.2010.498830. Epub 2010 Aug 20. No abstract available.

PMID:
20726686
20.
21.

Atypical metastatic profile in Stewart-Treves syndrome.

Almond MH, Jones RL, Thway K, Fisher C, Moskovic E, Judson IR.

Acta Oncol. 2010 Nov;49(8):1388-90. doi: 10.3109/0284186X.2010.491089. Epub 2010 Jun 4. No abstract available.

PMID:
20524777
22.

Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma.

Minchom A, Jones RL, Fisher C, Al-Muderis O, Ashley S, Scurr M, Karavasilis V, Judson IR.

Sarcoma. 2010;2010:264360. doi: 10.1155/2010/264360. Epub 2010 May 20.

23.

Chemotherapy in clear cell sarcoma.

Jones RL, Constantinidou A, Thway K, Ashley S, Scurr M, Al-Muderis O, Fisher C, Antonescu CR, D'Adamo DR, Keohan ML, Maki RG, Judson IR.

Med Oncol. 2011 Sep;28(3):859-63. doi: 10.1007/s12032-010-9502-7.

PMID:
20390470
24.

Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma.

Jones RL, McCall J, Adam A, O'Donnell D, Ashley S, Al-Muderis O, Thway K, Fisher C, Judson IR.

Eur J Surg Oncol. 2010 May;36(5):477-82. doi: 10.1016/j.ejso.2009.12.005. Epub 2010 Jan 8.

PMID:
20060679
25.

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.

Pacey S, Ratain MJ, Flaherty KT, Kaye SB, Cupit L, Rowinsky EK, Xia C, O'Dwyer PJ, Judson IR.

Invest New Drugs. 2011 Jun;29(3):481-8. doi: 10.1007/s10637-009-9367-9. Epub 2009 Dec 18.

PMID:
20016927
26.

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.

Baird RD, Kitzen J, Clarke PA, Planting A, Reade S, Reid A, Welsh L, López Lázaro L, de las Heras B, Judson IR, Kaye SB, Eskens F, Workman P, deBono JS, Verweij J.

Mol Cancer Ther. 2009 Jun;8(6):1430-7. doi: 10.1158/1535-7163.MCT-08-1167. Epub 2009 Jun 9.

27.

Eligibility of patients with brain metastases for phase I trials: time for a rethink?

Carden CP, Agarwal R, Saran F, Judson IR.

Lancet Oncol. 2008 Oct;9(10):1012-7. doi: 10.1016/S1470-2045(08)70257-2.

PMID:
19071257
28.

Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.

Judson IR.

J Clin Oncol. 2008 Nov 20;26(33):5322-5. doi: 10.1200/JCO.2008.17.7725. Epub 2008 Oct 27. No abstract available.

PMID:
18955449
29.

Late widespread skeletal metastases from myxoid liposarcoma detected by MRI only.

Hanna SA, Qureshi YA, Bayliss L, David LA, O'Donnell P, Judson IR, Briggs TW.

World J Surg Oncol. 2008 Jun 18;6:62. doi: 10.1186/1477-7819-6-62.

30.
31.
32.

Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.

Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, Griffiths JR, Judson IR, Workman P, Leach MO, Beloueche-Babari M.

Neoplasia. 2008 Apr;10(4):303-13.

33.

A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.

Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S, Aziz N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, de Bono JS.

Clin Cancer Res. 2008 Apr 1;14(7):2075-81. doi: 10.1158/1078-0432.CCR-07-1466.

34.

Humors of tumors: potential for interaction between cancer type and treating oncologist's personality?

Carden CP, Judson IR.

J Clin Oncol. 2008 Mar 20;26(9):1566-7. doi: 10.1200/JCO.2007.15.6711. No abstract available.

PMID:
18349414
35.

Imatinib for patients with liver or kidney dysfunction: no need to modify the dose.

Judson IR.

J Clin Oncol. 2008 Feb 1;26(4):521-2. doi: 10.1200/JCO.2007.14.5110. No abstract available.

PMID:
18235112
36.

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG.

Lancet Oncol. 2007 Jul;8(7):595-602.

PMID:
17586092
37.

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.

Verweij J, Casali PG, Kotasek D, Le Cesne A, Reichard P, Judson IR, Issels R, van Oosterom AT, Van Glabbeke M, Blay JY.

Eur J Cancer. 2007 Apr;43(6):974-8. Epub 2007 Mar 2.

PMID:
17336514
38.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.

Lancet. 2006 Oct 14;368(9544):1329-38.

PMID:
17046465
39.
40.

A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies.

Lee CP, de Jonge MJ, O'Donnell AE, Schothorst KL, Hanwell J, Chick JB, Brooimans RA, Adams LM, Drolet DW, de Bono JS, Kaye SB, Judson IR, Verweij J.

Clin Cancer Res. 2006 May 1;12(9):2841-8.

41.

Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.

Al-Saffar NM, Troy H, Ramírez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL.

Cancer Res. 2006 Jan 1;66(1):427-34.

42.

Differential sensitivity of liposarcoma subtypes to chemotherapy.

Jones RL, Fisher C, Al-Muderis O, Judson IR.

Eur J Cancer. 2005 Dec;41(18):2853-60. Epub 2005 Nov 10.

PMID:
16289617
43.

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR.

J Clin Oncol. 2005 Aug 20;23(24):5795-804.

PMID:
16110036
44.

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR; EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group.

Eur J Cancer. 2005 Aug;41(12):1751-7.

PMID:
16098458
45.

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P; Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK.

Br J Cancer. 2005 May 9;92(9):1599-610.

46.

The development and application of imatinib.

Jones RL, Judson IR.

Expert Opin Drug Saf. 2005 Mar;4(2):183-91. Review.

PMID:
15794712
47.

Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital.

Spurrell EL, Fisher C, Thomas JM, Judson IR.

Ann Oncol. 2005 Mar;16(3):437-44. Epub 2005 Jan 14.

PMID:
15653701
48.

Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours.

McSheehy PM, Port RE, Rodrigues LM, Robinson SP, Stubbs M, van der Borns K, Peters GJ, Judson IR, Leach MO, Griffiths JR.

Cancer Chemother Pharmacol. 2005 Feb;55(2):117-28. Epub 2004 Oct 5.

PMID:
15592719
49.

Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials.

Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson G, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin G, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P.

Br J Radiol. 2003;76 Spec No 1:S87-91. Review. No abstract available.

PMID:
15456718
50.

Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.

Chung YL, Troy H, Judson IR, Leek R, Leach MO, Stubbs M, Harris AL, Griffiths JR.

Clin Cancer Res. 2004 Jun 1;10(11):3863-70.

Supplemental Content

Loading ...
Support Center